Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXD93K)

• Drug Name: ARRY-614 Drug Info
• Synonyms: Pexmetinib; 945614-12-0; ARRY-614; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-

Indication

Disease Entry	ICD 11	Status	REF
Arthritis	FA20	Discontinued in Phase 1	[1]
Myelodysplastic syndrome	2A37	Discontinued in Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 24765037
  CAS Number: CAS 945614-12-0
  TTD Drug ID: DMXD93K

Molecule-Related Drug Atlas

Drug(s) Targeting Stress-activated protein kinase (p38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-07265803	DM3E6Q4	Dilated cardiomyopathy	BC43.0	Phase 3	[3]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[4]
BMS-582949	DMGYXFP	Atherosclerosis	BD40	Phase 2	[5]
AZD7624	DMEW3K9	Chronic obstructive pulmonary disease	CA22	Phase 2	[6]
GSK2269557	DMIN0SV	Asthma	CA23	Phase 2	[7]
TAK-715	DMZKPI8	Rheumatoid arthritis	FA20	Phase 2	[8]
MW150	DMBRVXB	Alzheimer disease	8A20	Phase 2	[9]
LY-2228820	DMHXTNW	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
PUR1800	DM6H10N	Chronic obstructive pulmonary disease	CA22	Phase 1	[11]
TA-5493	DMFES2K	Inflammation	1A00-CA43.1	Discontinued in Phase 1	[12]

Drug(s) Targeting Angiopoietin 1 receptor (TEK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AKB-9778	DMKNRYH	Diabetic macular edema	9B71.02	Phase 2	[13]
DCC-2036	DMJKFNU	Chronic myeloid leukaemia	2A20	Phase 1/2	[14]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
CEP-11981	DMYDTJ6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[17]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[17]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[17]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[17]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[18]
(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	DMFO8DR	Discovery agent	N.A.	Investigative	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin 1 receptor (TEK)	TT9VGXW	TIE2_HUMAN	Modulator	[2]
Stress-activated protein kinase (p38)	TTWELHI	NOUNIPROTAC	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026289)
• [2] Cmpany report (Arraybiopharma)
• [3] Clinical pipeline report, company report or official report of Pfizer
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
• [6] Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
• [7] Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70.
• [8] Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94.
• [9] p38alpha MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10245-E10254.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).
• [11] Clinical pipeline report, company report or official report of Pulmatrix Lexington, MA
• [12] US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
• [17] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [18] Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
• [19] Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.